Genetic test could match men to more effective cancer drug
NCT ID NCT02955082
Summary
This study is testing if a genetic test can identify men with advanced prostate cancer who might benefit most from a specific chemotherapy drug called carboplatin. It involves men whose cancer has spread and stopped responding to standard hormone therapies. The goal is to see if having certain inherited genetic changes predicts a better response to this treatment, which could help personalize future care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE-REFRACTORY PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Cancer Research and Royal Marsden Hospital
Sutton, Surrey, SM2 5PT, United Kingdom
Conditions
Explore the condition pages connected to this study.